A Multicentric, Randomized, Phase II Study Evaluating the Combination of METFORMIN With TAXOTERE+ Metformin Placebo Versus TAXOTERE + Metformin for the Treatment of Metastatic Hormone-refractory Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Docetaxel (Primary) ; Metformin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms TAXOMET
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 31 Aug 2018 Biomarkers information updated
- 04 Jun 2018 Status changed from active, no longer recruiting to completed.